Quantum Genomics Financials
| ALQGC Stock | EUR 0.07 0 1.77% |
Quantum |
Understanding current and past Quantum Genomics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Quantum Genomics' financial statements are interrelated, with each one affecting the others. For example, an increase in Quantum Genomics' assets may result in an increase in income on the income statement.
Quantum Genomics Stock Summary
Quantum Genomics competes with Poxel SA, Biophytis, Gensight Biologics, OSE Pharma, and Nanobiotix. Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. QUANTUM GENOMICS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 13 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0011648971 |
| Business Address | 33 rue Marbeuf, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.quantum-genomics.com |
| Phone | 33 1 85 34 77 70 |
| Currency | EUR - Euro |
You should never invest in Quantum Genomics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Quantum Stock, because this is throwing your money away. Analyzing the key information contained in Quantum Genomics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Quantum Genomics Key Financial Ratios
Quantum Genomics' financial ratios allow both analysts and investors to convert raw data from Quantum Genomics' financial statements into concise, actionable information that can be used to evaluate the performance of Quantum Genomics over time and compare it to other companies across industries.| Return On Equity | -1.23 | |||
| Return On Asset | -0.48 | |||
| Target Price | 8.8 | |||
| Beta | 0.27 | |||
| Z Score | 11.4 |
Quantum Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Quantum Genomics's current stock value. Our valuation model uses many indicators to compare Quantum Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Quantum Genomics competition to find correlations between indicators driving Quantum Genomics's intrinsic value. More Info.Quantum Genomics SA is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Quantum Genomics' earnings, one of the primary drivers of an investment's value.Quantum Genomics Systematic Risk
Quantum Genomics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Quantum Genomics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Quantum Genomics correlated with the market. If Beta is less than 0 Quantum Genomics generally moves in the opposite direction as compared to the market. If Quantum Genomics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Quantum Genomics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Quantum Genomics is generally in the same direction as the market. If Beta > 1 Quantum Genomics moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.